Cargando…
CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4. Former selective co-receptor antagonists, acting at early stages of infection, are able to impair the receptor functions, preventing the viral...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384722/ https://www.ncbi.nlm.nih.gov/pubmed/30717348 http://dx.doi.org/10.3390/molecules24030550 |
_version_ | 1783397044195426304 |
---|---|
author | Grande, Fedora Occhiuzzi, Maria Antonietta Rizzuti, Bruno Ioele, Giuseppina De Luca, Michele Tucci, Paola Svicher, Valentina Aquaro, Stefano Garofalo, Antonio |
author_facet | Grande, Fedora Occhiuzzi, Maria Antonietta Rizzuti, Bruno Ioele, Giuseppina De Luca, Michele Tucci, Paola Svicher, Valentina Aquaro, Stefano Garofalo, Antonio |
author_sort | Grande, Fedora |
collection | PubMed |
description | HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4. Former selective co-receptor antagonists, acting at early stages of infection, are able to impair the receptor functions, preventing the viral spread toward AIDS. Due to the capability of HIV to develop resistance by switching from CCR5 to CXCR4, dual co-receptor antagonists could represent the next generation of AIDS prophylaxis drugs. We herein present a survey on relevant results published in the last few years on compounds acting simultaneously on both co-receptors, potentially useful as preventing agents or in combination with classical anti-retroviral drugs based therapy. |
format | Online Article Text |
id | pubmed-6384722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63847222019-02-23 CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy Grande, Fedora Occhiuzzi, Maria Antonietta Rizzuti, Bruno Ioele, Giuseppina De Luca, Michele Tucci, Paola Svicher, Valentina Aquaro, Stefano Garofalo, Antonio Molecules Review HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4. Former selective co-receptor antagonists, acting at early stages of infection, are able to impair the receptor functions, preventing the viral spread toward AIDS. Due to the capability of HIV to develop resistance by switching from CCR5 to CXCR4, dual co-receptor antagonists could represent the next generation of AIDS prophylaxis drugs. We herein present a survey on relevant results published in the last few years on compounds acting simultaneously on both co-receptors, potentially useful as preventing agents or in combination with classical anti-retroviral drugs based therapy. MDPI 2019-02-02 /pmc/articles/PMC6384722/ /pubmed/30717348 http://dx.doi.org/10.3390/molecules24030550 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Grande, Fedora Occhiuzzi, Maria Antonietta Rizzuti, Bruno Ioele, Giuseppina De Luca, Michele Tucci, Paola Svicher, Valentina Aquaro, Stefano Garofalo, Antonio CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy |
title | CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy |
title_full | CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy |
title_fullStr | CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy |
title_full_unstemmed | CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy |
title_short | CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy |
title_sort | ccr5/cxcr4 dual antagonism for the improvement of hiv infection therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384722/ https://www.ncbi.nlm.nih.gov/pubmed/30717348 http://dx.doi.org/10.3390/molecules24030550 |
work_keys_str_mv | AT grandefedora ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT occhiuzzimariaantonietta ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT rizzutibruno ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT ioelegiuseppina ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT delucamichele ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT tuccipaola ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT svichervalentina ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT aquarostefano ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy AT garofaloantonio ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy |